SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-22-008843
Filing Date
2022-05-16
Accepted
2022-05-16 07:00:10
Documents
14
Period of Report
2022-05-16
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K plx-20220516x8k.htm   iXBRL 8-K 40801
2 EX-99.1 plx-20220516xex99d1.htm EX-99.1 162186
3 GRAPHIC plx-20220516xex99d1001.jpg GRAPHIC 5450
  Complete submission text file 0001558370-22-008843.txt   346881

Data Files

Seq Description Document Type Size
4 EX-101.SCH plx-20220516.xsd EX-101.SCH 3193
5 EX-101.LAB plx-20220516_lab.xml EX-101.LAB 16160
6 EX-101.PRE plx-20220516_pre.xml EX-101.PRE 10905
8 EXTRACTED XBRL INSTANCE DOCUMENT plx-20220516x8k_htm.xml XML 4870
Mailing Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601
Business Address 2 UNIVERSITY PLAZA SUITE 100 HACKENSACK NJ 07601 201-696-9345
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

IRS No.: 650643773 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 22925366
SIC: 2836 Biological Products, (No Diagnostic Substances)